ALVOTECH
Biopharmaceutical co. focused on the development & manufacturing of biosimilar medicines
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.
Reported lobbying by year
Filings
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Report 3rd Quarter 2026
|
CGCN GROUP, LLC | $60,000 reported |
|
Registration 3rd Quarter 2026
|
CGCN GROUP, LLC | — reported |
|
2nd Quarter - Termination (No Activity) 2nd Quarter 2022
|
MEHLMAN CONSULTING, INC. | — reported |
|
1st Quarter - Report (No Activity) 1st Quarter 2022
|
MEHLMAN CONSULTING, INC. | — reported |
|
4th Quarter - Report 4th Quarter 2021
|
MEHLMAN CONSULTING, INC. | $30,000 reported |
|
3rd Quarter - Report 3rd Quarter 2021
|
MEHLMAN CONSULTING, INC. | $50,000 reported |
|
2nd Quarter - Report 2nd Quarter 2021
|
MEHLMAN CONSULTING, INC. | $40,000 reported |
|
Registration 2nd Quarter 2021
|
MEHLMAN CONSULTING, INC. | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| MEHLMAN CONSULTING, INC. | 5 | $120,000 |
| CGCN GROUP, LLC | 1 | $60,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 6 |
| Copyright/Patent/Trademark | CPT | 4 |
| Tariff (miscellaneous tariff bills) | TAR | 2 |
| Manufacturing | MAN | 2 |
Bills named in its filings
Bill numbers found in the filers' descriptions, most often named first.
| Bill | Congress | Times named |
|---|---|---|
| S. 2891 | 117th | 1 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.